FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPRO	VAL							
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Name and Address of Reporting Person*						2. Is	2. Issuer Name and Ticker or Trading Symbol									Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Lovell Stephanie							Cyclerion Therapeutics, Inc. [CYCN]									X	Direc	•	10%	Owner	
(Last) (First) (Middle) C/O CYCLERION THERAPEUTICS, INC.							3. Date of Earliest Transaction (Month/Day/Year) 04/01/2019										Office below	er (give title v)	Othe below	r (specify v)	
301 BINNEY STREET (Street) CAMBRIDGE MA 02142						4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)		(Stat	e) (2	Zip)																	
			Tabl	e I - Nor	า-Deriv	ative	Se	curiti	es Ac	quired,	Dis	posed o	f, or	Ben	efici	ally (Owne	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)							Execut			Code	Transaction Disposed Code (Instr. 5)		ities Acquired (A) d Of (D) (Instr. 3,			nd	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	Amount		(A) or (D)	Price	- 1	Transaction(s) (Instr. 3 and 4)			(111501.4)					
Common Stock 04/01/						L/2019	9					2,421		A \$0.0		.00 2,421		D			
			Та	ble II - D	Derivat e.g., pı	ive S uts, c	ecu alls	ırities s, war	Acqu rants,	ired, D option	ispo is, c	sed of, onvertib	or B	enefi ecuri	ciall ties)	y Ov	vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercis Price of Derivative Security	on I	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date, Trans Code			n of Deri Secu Acqu (A) o Disp of (E	of		Exercis on Dat Day/Ye		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		str. 3			9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
						Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nur of	ount nber res						

Explanation of Responses:

1. Represents a restricted stock award that vests as to 100% of the shares of Common Stock on May 30, 2019, subject to the director's continuing service to the Company through the vesting date.

Remarks:

/s/ Larry Miller, Attorney-in-

<u>Fact</u>

** Signature of Reporting Person

Date

04/03/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.